EXAS

Exact Sciences Merged with Abbott, Delisted from Nasdaq

Exact Sciences to Merge with Abbott Laboratories

Exact Sciences Shareholders Approve Merger with Abbott Laboratories

Exact Sciences Reports Strong Q4 and Full-Year 2025 Results and Announces Pending Merger with Abbott

Exact Sciences Announces Updated Financial Projections for Merger with Abbott Laboratories

Exact Sciences Announces Executive Compensation Adjustments Ahead of Merger with Abbott

Abbott to Acquire Exact Sciences in $21 Billion Deal

Exact Sciences Reports Strong Third Quarter 2025 Results

Exact Sciences Announces Second Quarter 2025 Results and Strategic Collaborations

Exact Sciences Approves Incentive Plans and Shareholder Votes at 2025 Annual Meeting

Exact Sciences Announces Strong Q1 2025 Results and Raises Guidance

Exact Sciences Appoints New Board Member Leslie Trigg

Exact Sciences Reports 2024 Revenue and Fourth Quarter Results

Exact Sciences Announces Preliminary Financial Results and New Credit Agreement

Exact Sciences Appoints Kim Popovits to Board of Directors

Exact Sciences Announces Third-Quarter 2024 Financial Results: Revenue Growth and Regulatory Approvals

Exact Sciences Reports Q2 2024 Results with Record Revenue and Adjusted EBITDA

Exact Sciences Announces 2024 Annual Meeting Shareholder Approvals

Exact Sciences Announces Leadership Changes and Reiterates Financial Guidance

Exact Sciences Announces First-Quarter 2024 Financial Results

Exact Sciences Files Prospectus Supplement for Share Resale

Dr. Freda Lewis-Hall to Retire from Exact Sciences Board

Exact Sciences Completes Debt Exchange Transaction

Exact Sciences Appoints Aaron Bloomer as New CFO

Exact Sciences Announces Record Revenue and Positive Free Cash Flow for Q4 2023

Exact Sciences Announces Preliminary Q4 2023 Results and CFO Succession Plan